Mirivadelgat

DRUG2 trials

Sponsors

Helse Bergen HF, Foresee Pharmaceuticals Co., Ltd.

Conditions

Group 3 Pulmonary HypertensionParkinson's Disease

Phase 2

Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)

RecruitingNCT06475781

Foresee Pharmaceuticals Co., Ltd.Group 3 Pulmonary Hypertension

Start: 2025-03-01End: 2028-02-01Target: 126Updated: 2026-08-11

A randomized, Phase 2a, double-blinded, biomarker-driven, placebo-controlled study to assess safety, CNS penetration, and target engagement of Mirivadelgat in Parkinson’s disease – SLEIPNIR-2, a sub-protocol in the SLEIPNIR platform trial

Not yet recruitingCTIS2025-523570-17-00

Helse Bergen HFParkinson's Disease

Target: 45Updated: 2026-06-02